Update on the role of alpha-agonists in glaucoma management

Experimental Eye Research

Volumn 93, Issue 3, 2011, Pages 271-283

  Arthur, Stella ^a   Cantor, Louis B ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha agonists; Compliance and cost of alpha agonists; Fixed combinations; Glaucoma; Monotherapy; Neuroprotection; Ocular blood flow; Safety and efficacy

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; DIPIVEFRINE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST;

ALLERGIC REACTION; APHAKIA; APNEA; ARTICLE; ATAXIA; BRADYCARDIA; CONJUNCTIVITIS; CONTACT DERMATITIS; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE BURNING; EYE DISCOMFORT; EYE IRRITATION; FATIGUE; GLAUCOMA; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPEREMIA; HYPERTENSION; HYPOTENSION; HYPOTHERMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRRITABILITY; LETHARGY; MIOSIS; MONOTHERAPY; MUSCLE HYPOTONIA; NEUROPROTECTION; NONHUMAN; OCULAR PRURITUS; PALLOR; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; SIDE EFFECT; SOMNOLENCE; TACHYPHYLAXIS; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; DRUG COSTS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; REGIONAL BLOOD FLOW;

EID: 80054946438     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.04.002     Document Type: Article

References (222)

1. Acheampong A.A., Shackleton M., John B., Burke J., Wheeler L., Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 2002, 30:421-429.
2. Acheampong A.A., Small D., Baumgarten V., Welty D., Tang-Liu D. Formulation effects on ocular absorption of brimonidine in rabbit eyes. J. Ocul. Pharmacol. Ther. 2003, 18:325-337.
3. Adkins J.C., Balfour J.A. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998, 12:225-241.
4. AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS) (12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma). Am. J. Ophthalmol. 2002, 134:499-512.
5. Ahlquist R.P. A study of the adrenotropic receptors. Am. J. Physiol. 1948, 153:586-600.
6. Albracht D.C., LeBlanc R.P., Cruz A.M., Lamping K.A., Siegel L.I., Stern K.L., Kelley E.P., Stoecker J.F. A double-masked comparison of betaxolol and dipivefrin for the treatment of increased intraocular pressure. Am. J. Ophthalmol. 1993, 116:307-313.
7. Al-Shahwan S., Al-Torbak A.A., Turkmani S., Al-Omran M., Al-Jadaan I., Edward D.P. Side-effect profile of brimonidine tartrate in children. Ophthalmology 2005, 112:2143. Epub 2005 Oct 12.
8. Alvarado J.A., Murphy C.G., Franse-Carman L., Chen J., Underwood J. Effect of beta-adrenergic agonists on paracellular width and fluid flow across outflow pathway cells. Invest. Ophthalmol. Vis. Sci. 1998, 39:1813-1822.
9. Angelov O.V., Wiese A.G., Tang-Liu D.D., Acheampong A.A., Ismail I.M., Brar B.S. Preclinical safety profile of brimonidine. Eur. J. Ophthalmol. 1996, 6:21-25.
10. Arici M.K., Sayici M., Toker M., Erdoĝan H., Topalkara A. A short term study of the additive effect of timolol and brimonidine on intraocular pressure. Eye 2002, 16:39-43.
11. Arieta C., Amaral M., Matuda E., Crosta C., de Carvalho Moreira Filho D., José N. Dorzolamide X apraclonidine in the prevention of the intraocular pressure spike after Nd: YAG laser posterior capsulotomy. Curr. Eye Res. 2002, 25:237-241.
12. Aung T., Oen F.T., Wong H.T., Chan Y.H., Khoo B.K., Liu Y.P., Ho C.L., See J., Thean L.H., Viswanathan A.C., Seah S.K., Chew P.T. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure. Br. J. Ophthalmol. 2004, 88:88-94.
13. Azuara-Blanco A., Araujo S.V., Lu D.W., Lesk M.R., Katz L.J., Spaeth G.L. Effects of apraclonidine on short-term outcome of glaucoma surgery. J. Glaucoma 1996, 5:117-119.
14. Ballintine E.J., Garner R.R. Improvement of the co-efficient of outflow in glaucomatous eyes. Prolonged local treatment with epinephrine. Arch. Ophthalmol. 1961, 66:314-317.
15. Barnebey H.S., Robin A.L., Zimmerman T.J., Morrison J.C., Hersh S.B., Lewis R.A., Coleman A.L., Cinotti D.J., Walt J., Chen K.S., et al. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology 1993, 100:1083-1088.
16. Barnes S.D., Campagna J.A., Dirks M.S., Doe E.A. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Ophthalmology 1999, 106:2033-2037.
17. Bexis S., Docherty J.R. Role of alpha (1)-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. Br. J. Pharmacol. 2008, 152:591-597.
18. Bill A. Early effects of epinephrine on aqueous humor dynamics in vervet monkeys. Exp. Eye Res. 1969, 8:35-43.
19. Blondeau P., Rousseau J.A. Allergic reactions to brimonidine in patients treated for glaucoma. Can. J. Ophthalmol. 2002, 37:21-26.
20. Bournias T.E., Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 2009, 116:1719-1724.
21. Bowman R.J., Cope J., Nischal K.K. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 2004, 18:24-26.
22. Burke J., Schwartz M. Preclinical evaluation of brimonidine. Surv. Ophthalmol. 1996, 41(Suppl. 1):S9-S18.
23. Butler P., Mannschreck M., Lin S., Hwang I., Alvarado J. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch. Ophthalmol. 1995, 113:293-296.
24. Byles D.B., Frith P., Salmon J.F. Anterior uveitis as a side effect of topical brimonidine. Am. J. Ophthalmol. 2000, 130:287-291.
25. Cantor L.B. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin. Pharmacother. 2000, 1:815-834.
26. Cantor L.B., Hoop J., Katz L.J., Flartey K., Alphagan/Betaxolol Clinical Success Study Group Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure. Clin. Ther. 2001, 23:1032-1039.
27. Cantor L.B. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther. Clin. Risk Manag. 2006, 2:337-346.
28. Cantor L.B., WuDunn D., Catoira-Boyle Y., Yung C.W. Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients. J. Glaucoma 2008, 17:529-534.
29. Cantor L.B., Safyan E., Liu C.C., Batoosingh A.L. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr. Med. Res. Opin. 2008, 24:2035-2043.
30. Cantor L.B., Liu C.C., Batoosingh A.L., Hollander D.A. Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies. Curr. Med. Res. Opin. 2009, 25:1615-1620.
31. Carlsen J.O., Zabriskie N.A., Kwon Y.H., Barbe M.E., Scott W.E. Apparent central nervous system depression in infants after the use of topical brimonidine. Am. J. Ophthalmol. 1999, 128:255-256.
32. Carlsson A.M., Chauhan B.C., Lee A.A., Leblanc R.P. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected]. Am. J. Ophthalmol. 1999, 128:697-701.
33. Carroll S.C., Gaskin B.J., Goldberg I., Danesh-Meyer H.V. Glaucoma prescribing trends in Australia and New Zealand. Clin. Experiment. Ophthalmol. 2006, 34:213-218.
34. Centofanti M., Manni G., Gregori D., Cocco F., Lorenzano D., Bucci M.G. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 2000, 238:302-305.
35. Chen T.C., Ang R.T., Grosskreutz C.L., Pasquale L.R., Fan J.T. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. Ophthalmology 2001, 108:1033-1038.
36. Chen M.J., Chou J.C., Hsu W.M., Liu J.H. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. J. Chin. Med. Assoc. 2003, 66:276-281.
37. Chevrier R.L., Assalian A., Duperré J., Lesk M.R. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Ophthalmic Surg. Lasers 1999, 30:199-204.
38. Chung H.S., Shin D.H., Birt C.M., Kim C., Lee D., Levin D.S., Hakimzadeh R., Juzych M.S. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes. Ophthalmology 1997, 104:1921-1925.
39. Collaborative Normal-Tension Glaucoma Study Group Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 1998, 126:487-497.
40. Coppens G., Stalmans I., Zeyen T., Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J. Pediatr. Ophthalmol. Strabismus 2009, 46:12-18.
41. Costagliola C., Parmeggiani F., Ciancaglini M., D'Oronzo E., Mastropasqua L., Sebastiani A. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Ophthalmologica 2003, 217:39-44.
42. Costagliola C.R., Costagliola dell'Omo R., dell'Omo R., Romano M.R., Rinaldi M., Zeppa L., Parmeggiani F. Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin. Pharmacother. 2009, 10:2663-2677.
43. Crassous P.A., Denis C., Paris H., Sénard J.M. Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives. Curr. Top. Med. Chem. 2007, 7:187-194.
44. Craven E.R., Walters T.R., Williams R., Chou C., Cheetham J.K., Schiffman R., Combigan Study Group Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 2005, 21:337-348.
45. Daubert G.P. Is brimonidine ophthalmic a safe therapy for infants?. J. Clin. Pharm. Ther. 2006, 31:289-292.
46. David R., Spaeth G.L., Clevenger C.E., Perell H.F., Siegel L.I., Henry J.C., Stiles M.C., Passo M.S., Stamper R.L., Walt J.G. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch. Ophthalmol. 1993, 111:1387-1390.
47. David R. Brimonidine (Alphagan): a clinical profile four years after launch. Eur. J. Ophthalmol. 2001, 11(Suppl. 2):S72-S77.
48. Day D.G., Hollander D.A. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma\or ocular hypertension. Curr. Med. Res. Opin. 2008, 24:1435-1442. Epub 2008 Apr 9.
49. Denis P., Lafuma A., Berdeaux G. Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database. Clin. Ophthalmol. 2008, 2:321-329.
50. Derick R.J., Robin A.L., Walters T.R., Barnebey H.S., Choplin N., Schuman J., Kelley E.P., Chen K., Stoecker J.F. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997, 104:131-136.
51. Docherty J.R. Subtypes of functional alpha1-adrenoceptor. Cell. Mol. Life Sci. 2010, 67:405-417.
52. Donello J.E., Padillo E.U., Webster M.L., Wheeler L.A., Gil D.W. Alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J. Pharmacol. Exp. Ther. 2001, 296:216-223.
53. Dong J.Q., Babusis D.M., Welty D.F., Acheampong A.A., Tang-Liu D., Whitcup S.M. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J. Ocul. Pharmacol. Ther. 2004, 20:285-292.
54. Dong C.J., Guo Y., Agey P., Wheeler L., Hare W.A. Alpha 2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest. Ophthalmol. Vis. Sci. 2008, 49:4515-4522. Epub 2008 Jun 19.
55. DuBiner H.B., Mroz M., Shapiro A.M., Dirks M.S., Brimonidine vs.Latanoprost Study Group A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin. Ther. 2001, 23:1969-1983.
56. Enyedi L.B., Freedman S.F. Safety and efficacy of brimonidine in children with glaucoma. J. AAPOS 2001, 5:281-284.
57. Evans D.W., Hosking S.L., Gherghel D., Bartlett J.D. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. Br. J. Ophthalmol. 2003, 87:1463-1465.
58. Feibel R.M. High incidence of topical allergic reactions to 1% apraclonidine. Arch. Ophthalmol. 1995, 113:1579-1580.
59. Feldman R.M., Tanna A.P., Gross R.L., Chuang A.Z., Baker L., Reynolds A., Prager T.C., Additivity Study Group Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology 2007, 114:1248-1254. Epub 2007 May 23.
60. Ferencz J.R., Gilady G., Harel O., Belkin M., Assia E.I. Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 2005, 243:877-880. Epub 2005 Mar 23.
61. Fiscella R.G., Green A., Patuszynski D.H., Wilensky J. Medical therapy cost considerations for glaucoma. Am. J. Ophthalmol. 2003, 136:18-25.
62. Fiscella R.G., Jensenb M.K. Cost analysis of glaucoma medications. Am. J. Ophthalmol. 2008, 145:1108-1109.
63. Friedman D.S., Wilson M.R., Liebmann J.M., Fechtner R.D., Weinreb R.N. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am. J. Ophthalmol. 2004, 138(3 Suppl):S19-S31.
64. Gao H., Qiao X., Cantor L.B., WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch. Ophthalmol. 2002, 120:797-803.
65. García-Feijoó J., Sáenz-Francés F., Martínez-de-la-Casa J.M., Méndez-Hernández C., Fernández-Vidal A., Calvo-González C., García-Sánchez J. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. Curr. Med. Res. Opin. 2010, 26:1599-1606.
66. Garner L.L., Johnstone W.W., Ballintine E.J., Carroll M.E. Effect of 2% levo-rotary epinephrine on the intraocular pressure of the glaucomatous eye. Arch. Ophthalmol. 1959, 62:230-238.
67. Geyer O., Schmidt K.G., Pianka P., Neudorfer M., Lazar M. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine. Graefes Arch. Clin. Exp. Ophthalmol. 2000, 238:149-152.
68. Gharagozloo N.Z., Relf S.J., Brubaker R.F. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 1988, 95:1217-1220.
69. Gilsbach R., Röser C., Beetz N., Brede M., Hadamek K., Haubold M., Leemhuis J., Philipp M., Schneider J., Urbanski M., Szabo B., Weinshenker D., Hein L. Genetic dissection of alpha2-adrenoceptor functions in adrenergic versus nonadrenergic cells. Mol. Pharmacol. 2009, 75:1160-1170.
70. Goñi F.J., Brimonidine/Timolol Fixed Combination Study Group 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur. J. Ophthalmol. 2005, 15:581-590.
71. Gordon R.N., Liebmann J.M., Greenfield D.S., Lama P., Ritch R. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy. Eye 1998, 12:697-700.
72. Greenfield D.S., Liebmann J.M., Ritch R. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J. Glaucoma 1997, 6:250-258.
73. Gross R.L., Pinyero A., Orengo-Nania S. Clinical experience with apraclonidine 0.5%. J. Glaucoma 1997, 6:298-302.
74. Harris A., Evans D.W., Cantor L.B., Martin B. Hemodynamic and visual field function effects of oral nifedipine in patients with normal-tension glaucoma. Am. J. Ophthalmol. 1997, 124:296-302.
75. Harris A., Sergott R.C., Spaeth G.L., Katz J.L., Shoemaker J.A., Martin B.J. Color Doppler analysis of ocular vessel blood velocity in normal tension glaucoma. Am. J. Ophthalmol. 1994, 118:642-649.
76. Harris A., Jonescu-Cuypers C.P. The impact of glaucoma medication on parameters of ocular perfusion. Curr. Opin. Ophthalmol. 2001, 12:131-137.
77. Harris A., Jonescu-Cuypers C.P., Kagemann L. Atlas of Ocular Blood Flow: Vascular Anatomy, Pathophysiology, and Metabolism 2003, Butterworth Heinemann, Philadelphia.
78. Hatanaka M., Grigera D.E., Barbosa W.L., Jordao M., Susanna R. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J. Glaucoma 2008, 17:674-679.
79. Heijl A., Leske M.C., Hyman L., Yang Z., Bengtsson B., For the EMGT Group Intraocular pressure reduction with a fixed treatment protocol in the early manifest glaucoma trial. Ophthalmology 2009, 116:2271-2276. Epub 2009 Oct 24.
80. Higginbotham E.J. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin. Ophthalmol. 2010, 4:1-9.
81. Higgins R.G., Brubaker R.F. Acute effect of epinephrine on aqueous humor formation in the timolol-treated normal eye as measured by fluorophotometry. Invest. Ophthalmol. Vis. Sci. 1980, 19:420-423.
82. Hill R.A., Minckler D.S., Lee M., Heuer D.K., Baerveldt G., Martone J.F. Apraclonidine prophylaxis for postcycloplegic intraocular pressure spikes. Ophthalmology 1991, 98:1083-1086.
83. Holmwood P.C., Chase R.D., Krupin T., Rosenberg L.F., Ruderman J.M., Tallman B.A., Brodstein D.E., Chopra H., Goldenfeld M. Apraclonidine and argon laser trabeculoplasty. Am. J. Ophthalmol. 1992, 114:19-22.
84. Hoyng P.F., Kitazawa Y. Medical treatment of normal tension glaucoma. Surv. Ophthalmol. 2002, 47(Suppl 1):S116-S124.
85. Ito T., Ohguro H., Mamiya K., Ohguro I., Nakazawa M. Effects of antiglaucoma drops on MMP and TIMP balance in conjunctival and subconjunctival tissue. Invest. Ophthalmol. Vis. Sci. 2006, 47:823-830.
86. Jampel H.D., Parekh P., Johnson E., Miller R. Chart documentation by general physicians of the glaucoma medications taken by their patients. Am. J. Ophthalmol. 2005, 2005(140):344-345.
87. Javitt J., Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. J. Glaucoma 2000, 9:398-408.
88. Javitt J.C., Schiffman R.M. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. J. Glaucoma 2000, 9:224-234.
89. Jonescu-Cuypers C.P., Harris A., Ishii Y., Kagemann L., Gazozi H.J., Rotenstreich Y., Chung H.S., Martin B. Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers. J. Ocul. Pharmacol. Ther. 2001, 17:199-205.
90. Kacere R.D., Dolan J.W., Brubaker R.F. Intravenous epinephrine stimulates aqueous formation in the human eye. Invest. Ophthalmol. Vis. Sci. 1992, 33:2861-2865.
91. Kalapesi F.B., Coroneo M.T., Hill M.A. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br. J. Ophthalmol. 2005, 89:758-763.
92. Kass M.A., Mandell A.I., Goldberg I., Paine J.M., Becker B. Dipivefrin and epinephrine treatment of elevated intraocular pressure: a comparative study. Arch. Ophthalmol. 1979, 97:1865-1866.
93. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish R.K., Wilson M.R., Gordon M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002, 120:701-713.
94. Kass M.A., Gordon M.O., Gao F., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.K., Miller J.P., Parrish R.K., Wilson M.R., Ocular Hypertension Treatment Study Group Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch. Ophthalmol. 2010, 128:276-287.
95. Katsimpris J.M., Siganos D., Konstas A.G., Kozobolis V., Georgiadis N. Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification. J. Cataract Refract. Surg. 2003, 29:2288-2294.
96. Katz L.J. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am. J. Ophthalmol. 1999, 127:20-26.
97. Katz L.J. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J. Glaucoma 2002, 11:119-126.
98. Katz L.J., Simmons S.T., Craven E.R. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension. Curr. Med. Res. Opin. 2007, 23:2971-2983.
99. Kaufman P.L., Gabelt B.T. Alpha-2-adrenergic effects on aqueous humor dynamics. J. Glaucoma 1995, 4:8-14.
100. Kent A.R., King L., Bartholomew L.R. Vitreous concentration of topically applied brimonidine-purite 0.15%. J. Ocul. Pharmacol. Ther. 2006, 22:242-246.
101. Kerr N.M., Gross K.A., Tombleson M., Danesh-Meyer H.V. Combination brimonidine and timolol. Ophthalmology 2010, 117. 193-193.e1.
102. Konstas A.G., Maltezos A., Mantziris D.A., Sine C.S., Stewart W.C. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients. Eye (Lond) 1999, 13:314-318.
103. Konstas A.G., Stewart W.C., Topouzis F., Tersis I., Holmes K.T., Stangos N.T. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am. J. Ophthalmol. 2001, 131:729-733.
104. Konstas A.G., Katsimpris I.E., Kaltsos K., Georgiadou I., Kordelou A., Nelson L.A., Stewart W.C. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Eye 2008, 22:1391-1397.
105. Krupin T., Liebmann J.M., Greenfield D.S., Rosenberg L.F., Ritch R., Yang J.W., Low-Pressure Glaucoma Study Group The Low-pressure Glaucoma Treatment Study (LoGTS). Study design and baseline characteristics of enrolled patients. Ophthalmology 2005, 112:376-385.
106. Kymes S.M., Kass M.A., Anderson D.R., Miller J.P., Gordon M.O., Ocular Hypertension Treatment Study Group (OHTS) Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am. J. Ophthalmol. 2006, 141:997-1008.
107. Lachkar Y., Migdal C., Dhanjil S. Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch. Ophthalmol. 1998, 116:1591-1594.
108. 2A-adrenergic receptor via " hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc. Natl. Acad. Sci. U S A 1997, 94:9950-9955.
109. Lafuma A., Berdeaux G. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database. Curr. Med. Res. Opin. 2008, 24:1519-1527. Epub 2008 Apr 14.
110. Lafuma A., Laurendeau C., Berdeaux G. Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database. J. Med. Econ. 2008, 11:485-497.
111. Lai Becker M., Huntington N., Woolf A.D. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics 2009, 123:e305-e311. Epub 2009 Jan 5.
112. LeBlanc R.P. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998, 105:1960-1967.
113. Lee A.J., McCluskey P. Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clin. Ophthalmol. 2008, 2:545-555.
114. Lee D.A. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension. Clin. Ther. 2000, 22:53-65.
115. Lee D.A., Gornbein J., Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group. J. Ocul. Pharmacol. Ther. 2000, 16:3-18.
116. Lee D.A., Gornbein J.A. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J. Glaucoma 2001, 10:220-226.
117. Lee D.A., Higginbotham E.J. Glaucoma and its treatment: a review. Am. J. Health Syst. Pharm. 2005, 62:691-699.
118. Leske M.C., Heijl A., Hussein M., Early Manifest Glaucoma Trial Group Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2003, 121:48-56.
119. Leske M.C. Open-angle glaucoma: an epidemiologic overview. Ophthalmic Epidemiol. 2007, 14:166-172.
120. Lewis R., Perkins T.W., Gangnon R., Kaufman P.L., Heatley G.A. The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine. Ophthalmology 1998, 105:2256-2259.
121. Lichter P.R., Musch D.C., Gillespie B.W., CIGTS Study Group, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001, 108:1943-1953.
122. Link R.E., Desai K., Hein L., Stevens M.E., Chruscinski A., Bernstein D., Barsh G.S., Kobilka B.K. Cardiovascular regulation in mice lacking α2-adrenergic receptor subtypes b and c. Science 1996, 273:803-805.
123. Liu C.J., Ko Y.C., Cheng C.Y., Chiu A.W., Chou J.C., Hsu W.M., Liu J.H. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Ophthalmology 2002, 109:2241-2247.
124. Liu C.J., Cheng C.Y., Ko Y.C., Hsu W.M. Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma. J. Chin. Med. Assoc. 2004, 67:465-471.
125. Liu J.H., Gallar J. In vivo cAMP level in rabbit iris-ciliary body after topical epinephrine treatment. Curr. Eye Res. 1996, 15:1025-1032.
126. Liu J.H., Medeiros F.A., Slight J.R., Weinreb R.N. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 2010, 117:2075-2079.
127. Loon S.C., Liew G., Fung A., Reid S.E., Craig J.C. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clin. Experiment. Ophthalmol. 2008, 36:281-289.
128. 2A-adrenergic receptor subtype. Science 1996, 273:801-803.
129. Manni G., Centofanti M., Sacchetti M., Oddone F., Bonini S., Parravano M., Bucci M.G. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J. Glaucoma 2004, 13:163-167.
130. Mayor-Torroglosa S., De la Villa P, Rodríguez M.E., López-Herrera M.P., Avilés-Trigueros M., García-Avilés A., de Imperial J.M., Villegas-Pérez M.P., Vidal-Sanz M. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest. Ophthalmol. Vis. Sci. 2005, 46:3825-3835.
131. McKinnon S.J., Goldberg L.D., Peeples P., Walt J.G., Bramley T.J. Current management of glaucoma and the need for complete therapy. Am. J. Manag. Care 2008, 14:S20-S27.
132. Melamed S., David R., Brimonidine Study Group II Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Clin. Ther. 2000, 22:103-111.
133. Mittag T.W., Tormay I. Drug responses of adenylate cyclase in iris ciliary body determined by adenine labeling. Invest. Ophthalmol. Vis. Sci. 1985, 26:39-40.
134. Moore D., Harris A., Wudunn D., Kheradiya N., Siesky B. Dysfunctional regulation of ocular blood flow: a risk factor for glaucoma?. Clin. Ophthalmol. 2008, 2:849-861.
135. Motolko M.A. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr. Med. Res. Opin. 2008, 24:2663-2667.
136. Mundorf T., Williams R., Whitcup S., Felix C., Batoosingh A. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 2003, 19:37-44.
137. Mungan N.K., Wilson T.W., Nischal K.K., Koren G., Levin A.V. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. J. AAPOS 2003, 7:69-70.
138. Netland P.A., Michael M., Rosner S.A., Katzman B., Macy J.I. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv. Ther. 2003, 20:20-30.
139. Nguyen E.V., Azar D., Papalkar D., McCluskey P. Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features. J. Glaucoma 2008, 17:40-42.
140. Nixon D.R., Yan D.B., Chartrand J.P., Piemontesi R.L., Simonyi S., Hollander D.A. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr. Med. Res. Opin. 2009, 25:1645-1653.
141. Noecker R.J., Herrygers L.A., Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004, 23:490-496.
142. Noecker R.J., Study Group for the Efficacy of Brimonidine in Geriatric Patients Brimonidine .2% as a replacement for beta blockers in geriatric patients with glaucoma. Adv. Ther. 2002, 19:91-97.
143. Olthoff C.M., Hoevenaars J.G., van den Borne B.W., Webers C.A., Schouten J.S. Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:235-243. Epub 2008 Sep 19.
144. Osborne S.A., Montgomery D.M., Morris D., McKay I.C. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye 2005, 2005(19):129-137.
145. Osborne N.N. Pathogenesis of ganglion " cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog. Brain Res. 2008, 173:339-352.
146. Papaconstantinou D., Georgalas I., Kourtis N., Pitsas C., Karmiris E., Koutsandrea C., Ladas I., Georgopoulos G. Preliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucoma. Clin. Ophthalmol. 2009, 3:227-230.
147. Philipp M., Brede M.E., Hadamek K., Gessler M., Lohse M.J., Hein L. Placental α2-adrenoceptors control vascular development at the interface between mother and embryo. Nat. Genet. 2002, 31:311-315.
148. Piascik M.T., Guarino R.D., Smith M.S., Soltis E.E., Saussy D.L., Perez D.M. The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J. Pharmacol. Exp. Ther. 1995, 275:1583-1589.
149. Piascik M.T., Perez D.M. Alpha1-adrenergic receptors: new insights and directions. J. Pharmacol. Exp. Ther. 2001, 298:403-410.
150. Prokosch V., Panagis L., Volk G.F., Dermon C., Thanos S. Alpha2-adrenergic receptors and their core involvement in the process of axonal growth in tretinal explants. Invest. Ophthalmol. Vis. Sci. 2010, Jun 30. Epub ahead of print.
151. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006, 90:262-267.
152. Razeghinejad M.R., Sawchyn A.K., Katz L.J. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin. Pharmacother. 2010, 11:959-968.
153. Reardon G., Schwartz G.F., Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am. J. Ophthalmol. 2004, 137:S3-S12.
154. Rein D.B., Zhang P., Wirth K.E., Lee P.P., Hoerger T.J., McCall N., Klein R., Tielsch J.M., Vijan S., Saaddine J. The economic burden of major adult visual disorders in the United States. Arch. Ophthalmol. 2006, 124:1754-1760.
155. Rein D.B., Wittenborn J.S., Lee P.P., Wirth K.E., Sorensen S.W., Hoerger T.J., Saaddine J.B. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 2009, 116:823-832.
156. Reis R., Queiroz C.F., Santos L.C., Avila M.P., Magacho L. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin. Ther. 2006, 28:552-559.
157. Reitsamer H.A., Posey M., Kiel J.W. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp. Eye Res. 2006, 82:405-415.
158. Robin A.L., Coleman A.L. Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate. Trans. Am. Ophthalmol. Soc. 1990, 88:149-159.
159. Robin A.L. Questions concerning the role of apraclonidine in the management of glaucoma. Arch. Ophthalmol. 1995, 113:712-714.
160. Robin A.L., Ritch R., Shin D., Smythe B., Mundorf T., Lehmann R.P. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. Trans. Am. Ophthalmol. Soc. 1995, 93:421-438.
161. Robin A.L., Ritch R., Shin D.H., Smythe B., Mundorf T., Lehmann R.P. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group. Am. J. Ophthalmol. 1995, 120:423-432.
162. Robin A.L. The role of alpha-agonists in glaucoma therapy. Curr. Opin. Ophthalmol. 1997, 8:42-49.
163. Robin A.L., Burnstein Y. Selectivity of site of action and systemic effects of topical alpha agonists. Curr. Opin. Ophthalmol. 1998, 9:30-33.
164. Rosa R.H., Hein T.W., Yuan Z., Xu W., Pechal M.I., Geraets R.L., Newman J.M., Kuo L. Brimonidine evokes heterogeneous vasomotor response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size goes small. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H231-H238.
165. Rosenberg L.F., Krupin T., Ruderman J., McDaniel D.L., Siegfried C., Karalekas D.P., Grewal R.K., Gieser D.K., Williams R. Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise. Ophthalmology 1995, 102:1312-1318.
166. Ruiz Lapuente C., Ruiz Lapuente A., Link B. Influence of topical brimonidine on visual field in glaucoma. Eur. J. Ophthalmol. 2001, 11(Suppl. 2):S67-S71.
167. Sall K.N., Greff L.J., Johnson-Pratt L.R., DeLucca P.T., Polis A.B., Kolodny A.H., Fletcher C.A., Cassel D.A., Boyle D.R., Skobieranda F. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003, 110:615-624.
168. Saylor M., McLoon L.K., Harrison A.R., Lee M.S. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch. Ophthalmol. 2009, 127:402-406.
169. Schenker H.I., Yablonski M.E., Podos S.M., Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch. Ophthalmol. 1981, 99:1212-1216.
170. Schmidt K.G., Klingmüller V., Gouveia S.M., Osborne N.N., Pillunat L.E. Short posterior ciliary artery, central retinal artery, and choroidal hemodynamics in brimonidine-treated primary open-angle glaucoma patients. Am. J. Ophthalmol. 2003, 136:1038-1048.
171. Schneider T.L., Brubaker R.F. Effect of chronic epinephrine on aqueous humor flow during the day and during sleep in normal healthy subjects. Invest. Ophthalmol. Vis. Sci. 1991, 32:2507-2510.
172. Schuman J.S. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv. Ophthalmol. 1996, 41(Suppl 1):S27-S37.
173. Schuman J.S. Short- and long-term safety of glaucoma drugs. Expert Opin. Drug Saf. 2002, 2:181-194.
174. Schuman J.S., Horwitz B., Choplin N.T., David R., Albracht D., Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch. Ophthalmol. 1997, 115:847-852.
175. Schuman J.S. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology 2000, 107:1171-1177.
176. Schuman J.S. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin. Ther. 2000, 22:167-208.
177. Schwartz G.F. Measuring persistency with drug therapy in glaucoma management. Am. J. Manag. Care 2002, 8:S237-S239.
178. Sebastiani A., Parmeggiani F., Costagliola C., Ciancaglini M., D'Oronzo E., Mastropasqua L. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma. Acta Ophthalmol. Scand. Suppl. 2002, 236:29-30.
179. Serle J.B. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv. Ophthalmol. 1996, 41(Suppl 1):S39-S47.
180. Serle J., Cantor L., Gross R., Katz J., Mundorf T., Noecker R., Severin T., Simmons S., Walt J., Casciano J., Evans S., Doyle J. Best practice treatment algorithm for primary open-angle glaucoma: implications for U.S. ophthalmology practice. Manag. Care Interface 2002, 15:37-48.
181. Sharpe E.D., Day D.G., Beischel C.J., Rhodes J.S., Stewart J.A., Stewart W.C. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br. J. Ophthalmol. 2004, 88:953-956.
182. Sherwood M.B., Craven E.R., Chou C., DuBiner H.B., Batoosingh A.L., Schiffman R.M., Whitcup S.M. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch. Ophthalmol. 2006, 124:1230-1238.
183. Shin D.H., Glover B.K., Cha S.C., Kim Y.Y., Kim C., Nguyen K.D. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am. J. Ophthalmol. 1999, 127:511-515.
184. Simmons S.T., Earl M.L., Alphagan/Xalatan Study Group Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002, 109:307-314.
185. Singh K.H., Shinde U.A. Development and evaluation of novel polymeric nanoparticles of brimonidine tartrate. Curr. Drug Deliv. 2010, May 24. Epub ahead of print.
186. Sleath B., Ballinger R., Covert D., Robin A.L., Byrd J.E., Tudor G. Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients. Am. J. Geriatr. Pharmacother. 2009, 7:67-73.
187. Solish A.M., DeLucca P.T., Cassel D.A., Kolodny A.H., Hustad C.M., Skobieranda F. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J. Glaucoma 2004, 13:149-157.
188. Stamer W.D., Huang Y., Seftor R.E., Svensson S.S., Snyder R.W., Regan J.W. Cultured human trabecular meshwork cells express functional alpha 2A adrenergic receptors. Invest. Ophthalmol. Vis. Sci. 1996, 37:2426-2433.
189. Starke K., Endo T., Taube H.D. Pre- and postsynaptic components in effect of drugs with alpha adrenoceptor affinity. Nature 1975, 254:440-441.
190. Stewart W.C., Ritch R., Shin D.H., Lehmann R.P., Shrader C.E., van Buskirk E.M. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group. Arch. Ophthalmol. 1995, 113:287-292.
191. Stewart W.C., Laibovitz R., Horwitz B., Stewart R.H., Ritch R., Kottler M. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Arch. Ophthalmol. 1996, 114:938-942.
192. Stewart W.C., Day D.G., Stewart J.A., Holmes K.T., Leech J.N., Rowan C.T., Schwartz G.F. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 2000, 16:557-564.
193. Stewart W.C., Sharpe E.D., Day D.G., Kolker A.E., Konstas A.G., Lee W.H., Rieser J.C., Chopra H., Holmes K.T. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 2000, 16:251-259.
194. Stewart W.C., Day D.G., Stewart J.A., Schuhr J., Latham K.E. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 2001, 131:631-635.
195. Sullivan-Mee M., Pensyl D., Alldredge B., Halverson K., Gerhardt G., Qualls C. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations. J. Ocul. Pharmacol. Ther. 2010, 26:355-360.
196. Thelen U., Buchholz P., Kimmich F. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany. Curr. Med. Res. Opin. 2009, 25:1003-1009.
197. Tsai J.C., McClure C.A., Ramos Se B.A., Schlundt D.G., Pichert J. Compliance barriers in glaucoma: a systematic classification. J. Glaucoma 2003, 12:393-449.
198. Tsai J.C., Chang H.W. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. J. Ocul. Pharmacol. Ther. 2005, 21:475-482.
199. Tsai J.C. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 2009, 116(Suppl 11):S30-S36.
200. Toris C.B., Tafoya M.E., Camras C.B., Yablonski M.E. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995, 102:456-461.
201. Toris C.B., Gleason M.L., Camras C.B., Yablonski M.E. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. 1995, 113:1514-1517.
202. Townsend D.J., Brubaker R.F. Immediate effects of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest. Ophthalmol. 1980, 19:256-266.
203. U.S.Preventive Services Task Force Screening for glaucoma: recommendation statement. Ann. Fam. Med. 2005, 3:171-172.
204. Varma D.R., Deng X.F. Cardiovascular alpha1-adrenoceptor subtypes: functions and signaling. Can. J. Physiol. Pharmacol. 2000, 78:267-292.
205. Ventura M.P., Saheb N.E., Solari H.P., Saraiva V.S., Vianna R.N., Burnier M.N. Cost considerations of the new fixed combinations for glaucoma medical therapy. J. Clin. Pharm. Ther. 2005, 30:251-254.
206. Vidal L., Díaz F., Villena A., Moreno M., Campos J.G., Pérez de Vargas I. Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine. Brain Res. Bull. 2010, 82:18-24.
207. 1D-adrenergic receptors exhibit different requirements for agonist and mitogen-activated protein kinase activation to regulate growth responses in rat 1 fibroblasts. J. Pharmacol. Exp. Ther. 2002, 300:83-90.
208. Walters T.R. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv. Ophthalmol. 1996, 41(Suppl 1):S19-S26.
209. Wang Y.L., Toris C.B., Zhan G., Yablonski M.E. Effects of topical epinephrine on aqueous humor dynamics in the cat. Exp. Eye Res. 1999, 68:439-445.
210. Wang M., Ramos B.P., Paspalas C.D., Shu Y., Simen A., Duque A., Vijayraghavan S., Brennan A., Dudley A., Nou E., et al. α2-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007, 129:397-410.
211. Weinreb R.N. Compliance with medical treatment of glaucoma. J. Glaucoma 1992, 1:134-136.
212. Wheeler L.A., Gil D.W., WoldeMussie E. Role of alpha-2 agonists in neuroprotection. Surv. Ophthalmol. 2003, 48(Suppl 1):S47-S51.
213. Whitson J.T., Henry C., Hughes B., Lee D.A., Terry S., Fechtner R.D. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J. Glaucoma 2004, 13:168-173.
214. Whitson J.T., Ochsner K.I., Moster M.R., Sullivan E.K., Andrew R.M., Silver L.H., Wells D.T., James J.E., Bosworth C.F., Dickerson J.E., Landry T.A., Bergamini M.V., Brimonidine 0.15% Study Group The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 2006, 113:1333-1339.
215. Wilensky J.T. The role of brimonidine in the treatment of open-angle glaucoma. Surv. Ophthalmol. 1996, 41(Suppl 1):S3-S7.
216. Williams G.C., Orengo-Nania S., Gross R.L. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J. Glaucoma 2000, 9:235-238.
217. WoldeMussie E., Ruiz G., Wijono M., Wheeler L.A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2001, 42:2849-2855.
218. Wright T.M., Freedman S.F. Exposure to topical apraclonidine in children with glaucoma. J. Glaucoma 2009, 18:395-398.
219. Yoles E., Wheeler L.A., Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. 1999, 40:65-73.
220. Yu M., Li Y., Liu X., Ling Y., Zheng X. Effect of 0.2% brimonidine on retinal blood flow. Yan Ke Xue Bao 2001, 17:42-45.
221. Yuen N.S., Cheung P., Hui S.P. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy. Jpn. J. Ophthalmol. 2005, 49:89-92.
222. Zabriskie N., Netland P.A., Brimonidine with Latanoprost Study Groups 1 and 2 Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Adv. Ther. 2003, 20:92-100.